Last reviewed · How we verify
ANAVEX2-73 Intravenous
ANAVEX2-73 is a small molecule that modulates sigma-1 receptors and muscarinic acetylcholine receptors, which may have neuroprotective effects.
ANAVEX2-73 is a small molecule that modulates sigma-1 receptors and muscarinic acetylcholine receptors, which may have neuroprotective effects. Used for Alzheimer's disease, Parkinson's disease.
At a glance
| Generic name | ANAVEX2-73 Intravenous |
|---|---|
| Sponsor | Anavex Life Sciences Corp. |
| Drug class | Sigma-1 receptor modulator |
| Target | Sigma-1 receptor, Muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By modulating sigma-1 receptors and muscarinic acetylcholine receptors, ANAVEX2-73 can potentially improve cognitive function and reduce neurodegeneration associated with various neurological disorders.
Approved indications
- Alzheimer's disease
- Parkinson's disease
Common side effects
- Dizziness
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANAVEX2-73 Intravenous CI brief — competitive landscape report
- ANAVEX2-73 Intravenous updates RSS · CI watch RSS
- Anavex Life Sciences Corp. portfolio CI